Astellas Pharma US Inc.’s third-largest selling drug mirabegron, sold as Myrbetriq extended-release tablets, Betanis and Betmiga by the innovator, is set for competition in the US as Zydus Lifesciences Limited and Lupin Limited prepare for a launch of generic versions of Myrbetriq.
A Myrbetriq Battle Is Brewing And Why It Matters
Lupin To Launch Liraglutide In 2025-26
Zydus and Lupin are gearing up for the US launch of a generic to Astellas Pharma’s blockbuster drug Myrbetriq (mirabegron) while Aurobindo expects a longer wait. Meanwhile, Torrent is preparing to defend its market share in chronic therapies in India as other companies increasingly target this segment
